Author

Guangxian You

Observed name: GUANGXIAN YOU

Observed institutions: Zhejiang Chinese Medical University, Taizhou Second People's Hospital, Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, Taizhou Central Hospital, Hangzhou Medical College

ORCID: 0000-0002-8215-0875

Observed ORCID: 0000-0002-8215-0875

OpenAlex ID: A5103957321

TTK inhibitor promotes radiosensitivity of liver cancer cells through p21

2021 · Haibo Zhang, Weiping Yao, et al. · Biochemical and Biophysical Research Communications · 39

Severe lymphopenia as a prognostic factor in rectal cancer patients receiving adjuvant chemoradiotherapy: a retrospective study

2023 · Minjun Zhang, Guangxian You, et al. · Scientific Reports · 22

PDF

Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy

2019 · Hongen Xu, Guangxian You, et al. · World Journal of Surgical Oncology · 18

PDF

The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer

2024 · Xixi Ying, Guangxian You, et al. · Translational Cancer Research · 11

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials

2024 · Yang Yang, Rongjun Shao, et al. · Radiotherapy and Oncology · 10

Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study

2024 · Lin Zheng, Yang Yang, et al. · Translational Lung Cancer Research · 4

TMEM33, an oncogene regulated by miR-214-3p, promotes the progression of lung adenocarcinoma through the Wnt/β-catenin signaling pathway

2024 · GUANGXIAN YOU, QIAO YANG, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 4

Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer

2024 · Xixi Ying, Zheng Shi, et al. · Neoplasma · 2

PDF

Inhibitory effect of STAT3 gene combined with CDDP on growth of human Wilms tumour SK-NEP-1 cells

2016 · Junrong Wang, Nina Zhang, et al. · Bioscience Reports · 2

Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1

2026 · Dongqing Lv, Ruiqing Zhu, et al. · Lung Cancer · 1

Association of socioeconomic status and nine modifiable lifestyle factors on esophageal cancer risk in European and East Asian populations — Evidence from a comprehensive Mendelian randomization study

2025 · Guangxian You, Ruizhi Ye, et al. · Nutrición Hospitalaria · 1

PDF

Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer

2024 · Xixi Ying, Zheng Shi, et al. · Neoplasma · 1

PDF

Delaying thoracic radiotherapy does not compromise overall survival in extensive-stage small cell lung cancer after first-line systemic treatment: a multicenter real-world cohort study

2026 · Lin Zheng, Xiaowei Le, et al. · Clinical and Translational Radiation Oncology

PDF

A Single-Arm Phase II Clinical Study of SBRT Combined with Tislelizumab and GM-CSF for Advanced Non-Small Cell Lung Cancer Progressing After Immunotherapy

2026 · Linggang Zhu, Lin Zheng, et al. · Research Square

PDF

Expression and clinical significance of ERBB4 in gastric cancer

2025 · Xiaofeng Zhou, Siyu Zhao, et al. · Journal of Gastrointestinal Oncology

Corrigendum to “TTK inhibitor promotes radiosensitivity of liver cancer cells through p21” [Biochem. Biophys. Res. Commun. 550(2021) 84–91]

2021 · Haibo Zhang, Weiping Yao, et al. · Biochemical and Biophysical Research Communications

Works count: 16

Citation count: 115

H-index: 5

I10-index: 5